Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.antiviral.2020.104902 http://scihub22266oqcxt.onion/10.1016/j.antiviral.2020.104902 32739404!7392080!32739404     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Antiviral+Res 2020 ; 182 (ä): 104902 Nephropedia Template TP {{tp|p=32739404|t=2020. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro |pdf=|usr=}}{{32739404}} gab.com Text The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro JO: Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=32739404 #FOAvip Cenicriviroc (CVC) is a small-molecule chemokine receptor antagonist with highly potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity through antagonizing C-C chemokine receptor type 5 (CCR5) as a coreceptor of HIV-1. CVC also strongly antagonizes C-C chemokine receptor type 2b (CCR2b), thereby it has potent anti-inflammatory and immunomodulatory effects. CVC is currently under clinical trials in the patients for treatment of nonalcoholic steatohepatitis, in which immune cell activation and dysregulation of proinflammatory cytokines play an important role in its pathogenesis. In this study, CVC was examined for its inhibitory effect on the replication of SARS-CoV-2, the causative agent of COVID-19, in cell cultures and found to be a selective inhibitor of the virus. The 50% effective concentrations of CVC were 19.0 and 2.9 muM in the assays based on the inhibition of virus-induced cell destruction and viral RNA levels in culture supernatants of the infected cells, respectively. Interestingly, the CCR5-specific antagonist maraviroc did not show any anti-SARS-CoV-2 activity. Although the mechanism of SARS-CoV-2 inhibition by CVC remains to be elucidated, CCR2b does not seem to be its target molecule. Considering the fact that the regulation of excessive immune activation is required to treat COVID-19 patients at the late stage of the disease, CVC should be further pursued for its potential in the treatment of SARS-CoV-2 infection. Twit Text FOAVip The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro ????Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=32739404 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32739404 #FOAvip English Wikipedia <ref>{{Cite pmid|32739404}}</ref> The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro #MMPMID32739404 Okamoto M; Toyama M; Baba M Antiviral Res 2020[Oct]; 182 (ä): 104902 PMID32739404show ga Cenicriviroc (CVC) is a small-molecule chemokine receptor antagonist with highly potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity through antagonizing C-C chemokine receptor type 5 (CCR5) as a coreceptor of HIV-1. CVC also strongly antagonizes C-C chemokine receptor type 2b (CCR2b), thereby it has potent anti-inflammatory and immunomodulatory effects. CVC is currently under clinical trials in the patients for treatment of nonalcoholic steatohepatitis, in which immune cell activation and dysregulation of proinflammatory cytokines play an important role in its pathogenesis. In this study, CVC was examined for its inhibitory effect on the replication of SARS-CoV-2, the causative agent of COVID-19, in cell cultures and found to be a selective inhibitor of the virus. The 50% effective concentrations of CVC were 19.0 and 2.9 muM in the assays based on the inhibition of virus-induced cell destruction and viral RNA levels in culture supernatants of the infected cells, respectively. Interestingly, the CCR5-specific antagonist maraviroc did not show any anti-SARS-CoV-2 activity. Although the mechanism of SARS-CoV-2 inhibition by CVC remains to be elucidated, CCR2b does not seem to be its target molecule. Considering the fact that the regulation of excessive immune activation is required to treat COVID-19 patients at the late stage of the disease, CVC should be further pursued for its potential in the treatment of SARS-CoV-2 infection. |Animals[MESH] |Antiviral Agents/pharmacology[MESH] |Betacoronavirus/*drug effects/*physiology[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Chlorocebus aethiops[MESH] |Coronavirus Infections/*drug therapy/*virology[MESH] |Humans[MESH] |Imidazoles/*pharmacology[MESH] |Maraviroc/pharmacology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/*virology[MESH] |Receptors, CCR2/*antagonists & inhibitors[MESH] |SARS-CoV-2[MESH] |Sulfoxides[MESH] |Vero Cells[MESH]The chemokine receptor antagonist cenicriviroc inhibits the replicatio(epmc).pdf DeepDyve Pubget Overpricing